← Rolf Wachter

Papers by Rolf Wachter

Page 2 · newest first

51. Real-world characteristics and use patterns of patients treated with vericiguat: A nationwide longitudinal cohort study in GermanyEuropean Journal of Clinical Pharmacology · 2024
52. Time to Recovery from Systolic Dysfunction Correlates with Left Ventricular Fibrosis in Arrhythmia-Induced CardiomyopathyLife · 2024
53. Circulating miR-let7a levels predict future diagnosis of chronic thromboembolic pulmonary hypertensionScientific Reports · 2024
54. Apixaban versus Aspirin for Embolic Stroke of Undetermined SourceNEJM Evidence · 2023
55. Impact of the COVID-19 pandemic on implementation of novel guideline-directed medical therapies for heart failure in Germany: a nationwide retrospective analysisThe Lancet Regional Health - Europe · 2023
56. Repurposing the β₃-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac DiseaseJAMA Cardiology · 2023
57. Early Initiation of Sacubitril/Valsartan in Patients With Acute Heart Failure and Renal Dysfunction: An Analysis of the TRANSITION StudyJournal of Cardiac Failure · 2023
58. Treatment response to spironolactone in patients with heart failure with preserved ejection fraction: a machine learning-based analysis of two randomized controlled trialsEBioMedicine · 2023
59. De Novo Lipogenesis-Related Monounsaturated Fatty Acids in the Blood Are Associated with Cardiovascular Risk Factors in HFpEF PatientsJournal of Clinical Medicine · 2023
60. Intensive heart rhythm monitoring to decrease ischemic stroke and systemic embolism—the Find-AF 2 study—rationale and designAmerican Heart Journal · 2023
61. Higher troponin T serum concentrations in hospital patients without diagnosed cardiac diseases compared to a population-based cohortClinical Chemistry and Laboratory Medicine (CCLM) · 2023
62. Comparison of quantitative flow ratio with instantaneous wave‐free ratio and resting full‐cycle ratio during daily routine in the catheterization laboratoryCatheterization and Cardiovascular Interventions · 2023
63. Longitudinal association between N-terminal B-type natriuretic peptide, anxiety and social support in patients with HFpEF: results from the multicentre randomized controlled Aldo-DHF trialBMC Cardiovascular Disorders · 2023
64. A cardiologist’s guide to machine learning in cardiovascular disease prognosis predictionBasic Research in Cardiology · 2023
65. Integrated Care for Older Multimorbid Heart Failure Patients: Protocol for the ESCAPE Randomized Trial and Cohort StudyESC Heart Failure · 2023
66. Echocardiography in acute stroke patients: a nationwide analysis in departments with certified stroke units in GermanyNeurological Research and Practice · 2023
67. Trans-fatty acid blood levels of industrial but not natural origin are associated with cardiovascular risk factors in patients with HFpEF: a secondary analysis of the Aldo-DHF trialClinical Research in Cardiology · 2023
68. Arrhythmia-induced cardiomyopathy (AIC) is a diagnosis ex juvantibus: study design and diagnostic criteria of a prospective, observational, multi-center study2022
69. Prolonged cardiac monitoring for stroke prevention: A systematic review and meta-analysis of randomized-controlled clinical trialsEuropean Stroke Journal · 2022
70. Trans-fatty acid blood levels of industrial but not natural origin are associated with cardiovascular risk factors in patients with HFpEF: a secondary analysis of the Aldo-DHF trial2022
71. Searching for atrial fibrillation: looking harder, looking longer, and in increasingly sophisticated ways. An EHRA position paperEP Europace · 2022
72. Biomarker Profiles in Heart Failure with Preserved vs. Reduced Ejection Fraction: Results from the DIAST-CHF StudyESC Heart Failure · 2022
73. Reduction in heart failure hospitalizations by sacubitril/valsartan; a post-hoc analysis of the PARALLAX trialEuropean Heart Journal · 2022
74. Saturated Fatty Acid Blood Levels and Cardiometabolic Phenotype in Patients with HFpEF: A Secondary Analysis of the Aldo-DHF TrialBiomedicines · 2022
75. Evaluation of the HFA-PEFF Score: Results from the Prospective DIAST-CHF CohortESC Heart Failure · 2022
76. Monitoring for atrial fibrillation prior to patent foramen ovale closure after cryptogenic strokeInternational Journal of Stroke · 2022
77. Attenuation of the Heartbeat-Evoked Potential in Patients With Atrial FibrillationJACC. Clinical electrophysiology · 2022
78. Sacubitril/Valsartan in Heart Failure: Efficacy and Safety in and Outside Clinical TrialsESC Heart Failure · 2022
79. Comorbidities in heart failure with preserved ejection fractionHerz · 2022
80. Prevalence and prognostic impact of chronic kidney disease and anaemia across ACC/AHA precursor and symptomatic heart failure stagesClinical Research in Cardiology · 2022
81. Cohort Profile: The LIFE-Adult-StudyInternational Journal of Epidemiology · 2022
82. Early detection of atrial fibrillation in patients with heart failure reduces the risk of subsequent hospitalization: a subanalysis of the randomized TIM-HF2 trialEuropean Heart Journal - Digital Health · 2022
83. Current Challenges and Future Directions in Handling Stroke Patients With Patent Foramen Ovale—A Brief ReviewFrontiers in Neurology · 2022
84. Signs of left atrial disease and 10-year risk of atrial fibrillationPLoS ONE · 2022
85. Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS studyEuropean Heart Journal · 2022
86. Hospitalization for heart failure: a window of opportunityEuropean Heart Journal · 2022
87. Long-Term Follow-up of Enhanced Holter-Electrocardiography Monitoring in Acute Ischemic StrokeJournal of Stroke · 2021
88. NT-proBNP as a Marker for Atrial Fibrillation and Heart Failure in Four Observational Outpatient TrialsESC Heart Failure · 2021
89. Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of CardiologyENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2021
90. Revisited Upper Reference Limits for Highly Sensitive Cardiac Troponin T in Relation to Age, Sex, and Renal FunctionJournal of Clinical Medicine · 2021
91. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection FractionJAMA · 2021
92. How family history of premature myocardial infarction affects patients at cardiovascular risk.Health Psychology · 2021
93. Patients’ attitude towards a sham-controlled trial on pulmonary vein isolation in atrial fibrillationClinical Research in Cardiology · 2021
94. Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF TrialCells · 2021
95. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS) randomized trial – update of patient characteristics and study timeline after interim analysisEuropean Heart Journal · 2021
96. Influence of Baseline Parameters on One-Year Physical, Mental, and Health-Related Quality of Life in Patients with Heart Failure and Preserved Ejection FractionESC Heart Failure · 2021
97. Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients: the Aldo-DHF randomized controlled trialClinical Research in Cardiology · 2021
98. Echocardiographic Evaluation of LV Function in Patients with Tachyarrhythmia and Reduced Left Ventricular Function in Response to Rhythm RestorationJournal of Clinical Medicine · 2021
99. Inconsistent Findings of Cardiac Troponin T and I in Clinical Routine Diagnostics: Factors of InfluenceJournal of Clinical Medicine · 2021
100. Proteomics to improve phenotyping in obese patients with heart failure with preserved ejection fractionEuropean Journal of Heart Failure · 2021